A few days ago, the preliminary review results of the 2021 Beijing Science and Technology Award project award were publicized.
The 2021 Beijing Science and Technology Award project awards are divided into Natural Science Award, technological invention award and science and technology progress award.
Among them, the natural science award focuses on major scientific discoveries; The Technological Invention Award focuses on leading original technological breakthroughs and supporting the development of key areas in the city; The science and technology progress award focuses on key technology innovation, application and promotion, and achievements supporting the development of key areas in the city.
It can be seen from the list of recommended projects for the preliminary review of the 2021 Beijing Science and technology award that the research and development of the key technology of complex corneal blindness (Microk) and the standardization, promotion and application of artificial cornea won the first prize of the science and technology progress award.
For a long time, the selection of the first prize of the science and technology progress award has always adhered to the principle of "rather lack than abuse", and the awards are quite valuable.
In 2021, the city won the first prize of 42 science and technology progress awards, and one of the research results of Michal medical won. Thanks to the incentives of relevant national policies, Michal medical R & D team creatively designed and developed the world's first artificial cornea without donor cornea.
Michaelis artificial cornea is suitable for patients with bilateral corneal blindness who are difficult to succeed in corneal transplantation, including corneal transplantation failure, severe keratoconjunctival scar vascularization caused by chemical injury, thermal burn, explosion injury, etc., eyelid atresia, serious autoimmune diseases (such as Stevens Johnson syndrome and cicatricial pemphigoid), corneal blindness caused by end-stage dry eye, etc, The product provides a new way for the clinical treatment of patients with contraindications to traditional corneal transplantation, also leads the development of this research direction in the world, and provides a theoretical basis and technical support for the development of artificial cornea.
Since its establishment, Mihe medical has continuously strengthened the independent innovation of the enterprise and strengthened the self-reliance and self-improvement of science and technology. It takes scientific and technological innovation as the top of the enterprise development strategy and as an important means to promote the high-quality development of the enterprise, adding bricks and tiles to the national ownership of [independent intellectual property rights of artificial cornea].
At the same time, with regard to the blind, Mihe medical has always adhered to the belief that "one person, a happy family and a group of people will be liberated", actively promoted the development of the cause of blind people's rehabilitation, enhanced their sense of gain, happiness and security, and helped them integrate into the society, so as to reduce the burden on the blind, their families and the society, and truly achieve "building a well-off society in an all-round way, there can be no less blind people!"